Cargando…

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label

Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation. In vitro metabolism data suggested osimertinib is a substrate of cytochrome P450 (CYP)3A4/5, a weak inducer of CYP3A, and an inhibitor of breast cancer resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pilla Reddy, Venkatesh, Walker, Michael, Sharma, Pradeep, Ballard, Peter, Vishwanathan, Karthick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980577/ https://www.ncbi.nlm.nih.gov/pubmed/29468841 http://dx.doi.org/10.1002/psp4.12289

Ejemplares similares

Erratum: Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
Publicado: (2019)

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction
por: Gill, Jaidip, et al.
Publicado: (2022)

Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer
por: Vishwanathan, Karthick, et al.
Publicado: (2019)

Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
por: Mulford, Darcy J., et al.
Publicado: (2023)

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
por: Grañana-Castillo, Sandra, et al.
Publicado: (2022)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
por: Zhou, Diansong, et al.
Publicado: (2019)

Evaluating the performance of machine‐learning regression models for pharmacokinetic drug–drug interactions
por: Gill, Jaidip, et al.
Publicado: (2022)

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam
por: Ren, Song, et al.
Publicado: (2021)

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide
por: Lüpfert, Christian, et al.
Publicado: (2018)

Building in-house PBPK modelling tools for oral drug administration from literature information
por: Grandoni, Silvia, et al.
Publicado: (2019)

Prospective Prediction of Dapaconazole Clinical Drug–Drug Interactions Using an In Vitro to In Vivo Extrapolation Equation and PBPK Modeling
por: Antunes, Natalícia de Jesus, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin
por: Park, Min-Ho, et al.
Publicado: (2017)

Prediction of Drug–Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
por: Ji, Beihong, et al.
Publicado: (2019)

Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends
por: Abouir, Kenza, et al.
Publicado: (2021)

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
por: Wang, Kun, et al.
Publicado: (2021)

Current PBPK Models: Are They Predicting Tissue Drug Concentration Correctly?
por: Ibarra, Manuel, et al.
Publicado: (2020)

PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus
por: Szeto, Ke Xu, et al.
Publicado: (2021)

Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring
por: Zapke, Sonja E., et al.
Publicado: (2021)

Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective
por: Riedmaier, Arian Emami, et al.
Publicado: (2020)

Machine learning-based quantitative prediction of drug exposure in drug-drug interactions using drug label information
por: Jang, Ha Young, et al.
Publicado: (2022)

Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
por: Shaik, Abdul Naveed, et al.
Publicado: (2019)

Mechanistic PBPK Modelling to Predict the Advantage of the Salt Form of a Drug When Dosed with Acid Reducing Agents
por: Chirumamilla, Siri Kalyan, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012)

An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling
por: Rowland Yeo, Karen, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat
por: Sánchez-Dengra, Bárbara, et al.
Publicado: (2021)

Development and application of a PBPK modeling strategy to support antimalarial drug development
por: Abla, Nada, et al.
Publicado: (2023)

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
por: Wu, Fan, et al.
Publicado: (2020)

PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction
por: Bolleddula, Jayaprakasam, et al.
Publicado: (2021)

Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery
por: Naga, Doha, et al.
Publicado: (2022)

Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery
por: Talkington, Anne M., et al.
Publicado: (2021)

Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation
por: Anoshchenko, Olena, et al.
Publicado: (2021)

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects
por: Asaumi, Ryuta, et al.
Publicado: (2018)

Pharmacogenetic information for patients on drug labels
por: Haga, Susanne B, et al.
Publicado: (2014)

Pharmaceutical excipients and the information on drug labels
por: Balbani, Aracy Pereira Silveira, et al.
Publicado: (2015)

Verification of the “Upward Variation in the Reporting Odds Ratio Scores” to Detect the Signals of Drug–Drug Interactions
por: Noguchi, Yoshihiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m8npd5go4orjvq2g7v8qckq113